GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has been running up the charts in recent months easily surpassing $100 a share and taking charge as the biggest pot stock on the markets. The stock recently got a boost after the Company announced Primary endpoint achieved in both Epidiolex doses with high statistical significance compared to placebo.
GWPH nearly tripled in March after the Company announced positive Phase 3 trial data for its drug Epidiolex, for the treatment of Dravet syndrome. This is big news for GW as the market for Epidiolex could exceed $1 billion. It also shows that cannabinoids can produce compelling and clinical important data and represent a highly promising new class of medications. GW saw its market valuation more than double from about $900 million to $1.8 billion on the news which has ignited the entire pot stock sector.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) is a biopharmaceutical company focused on discovering,